GCGary Cohen

Gary Cohen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gary Cohen has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Retrospective case-control analysis of the infectious complications of retained broken needles in people who inject drugs

    by Alex Ba Sandberg, Shalom Bs Mammen, Angela Udongwo, Daohai Yu, Xiaoning Lu, Ryan Do Graham, Gary Cohen, Hillel Maresky

    Retained broken needles (RBNs) in patients is a potentially underreported complication of intravenous drug use (IVDU) in people who inject drugs. Identification of RBNs poses a challenge for radiologists and clinicians due to subtle appearance on imaging and the complexities of patient presentations. A single-center case-control study was performed between January 1, 2021, and December 31, 2021. The cases included all patients with a history of IVDU who presented to the emergency department (ED) with RBNs. Data collected on the study population included RBN location and size, complications, and imaging modality. A control group of 2:1 matched on age, gender, and race/ethnicity with the cases was generated from patients with a history of IVDU from the same time period who had no RBNs. A total of 3920 total patients presented to ED with a history of IVDU and 70 patients were found to have RBN (1.8%). RBNs were most observed in the foot/ankle (32.9%) forearm (18.6%), and neck (17.1%). RBNs were found to be incidental in 82.9% (58 out of 70) of patients. Radiography located needle fragments (55.7%) slightly more often than CT (44.3%). Overall, among all the cases and controls combined, 33.8% had positive blood cultures. In the group of patients with a RBN, 47.1% presented with positive bacterial blood cultures during the hospital admission, whereas the group without an RBN showed 27.1% (P = .004). The RBN group showed significantly higher rates of abscess (72.9% vs 48.6%), cellulitis (70.0% vs 46.4%), and osteomyelitis (37.1% vs 13.6%) than the non-RBN group (all P ≤ .001). This study suggests that RBNs are likely underreported and patients with RBNs are at an increased risk of infectious complications. Increasing the awareness and refining our understanding of RBNs is crucial to mitigating these complications.


  • Open Access

    High Resolution CHEST CT(HRCT) Evaluation in Patients Hospitalized with COVID-19 Infection

    by Maulin Patel, Junad Chowdhury, Matthew Zheng, Osheen Abramian, Steven Verga, Huaqing Zhao, Nicole Patlakh, Nicholas Montecalvo, David Fleece, Gary Cohen, et al.

    Introduction: Currently the main diagnostic modality for COVID-19 (Coronavirus disease-2019) is reverse transcriptase polymerase chain reaction (RT-PCR) via nasopharyngeal swab which has high false negative rates. We evaluated the performance of high-resolution computed tomography (HRCT) imaging in the diagnosis of suspected COVID-19 infection compared to RT-PCR nasopharyngeal swab alone in patients hospitalized for suspected COVID-19 infection. Methods: This was a retrospective analysis of 324 consecutive patients admitted to Temple University Hospital. All hospitalized patients who had RT-PCR testing and HRCT were included in the study. HRCTs were classified as Category 1, 2 or 3. Patients were then divided into four groups based on HRCT category and RT-PCR swab results for analysis. Results: The average age of patients was 59.4 (±15.2) years and 123 (38.9%) were female. Predominant ethnicity was African American 148 (46.11%). 161 patients tested positive by RT-PCR, while 41 tested positive by HRCT. 167 (52.02%) had category 1 scan, 63 (19.63%) had category 2 scan and 91 (28.35%) had category 3 HRCT scans. There was substantial agreement between our radiologists for HRCT classification (κ = 0.64). Sensitivity and specificity of HRCT classification system was 77.6 and 73.7 respectively. Ferritin, LDH, AST and ALT were higher in Group 1 and D-dimers levels was higher in Group 3; differences however were not statistically significant. Conclusion: Due to its high infectivity and asymptomatic transmission, until a highly sensitive and specific COVID-19 test is developed, HRCT should be incorporated into the assessment of patients who are hospitalized with suspected COVID-19. Key Points: Key Question: Can High Resolution CT chest (HRCT) improve diagnostic accuracy of current Nasopharyngeal swab in suspected COVID-19 patients? Bottom Line: In this retrospective analysis, our novel HRCT classification identified 20% of all COVID-19 patients who had negative nasopharyngeal reverse transcriptase polymerase chain reaction (RT-PCR) tests but had HRCT findings consistent with COVID-19 pneumonia. These patients were ruled out for other infections and laboratory markers were similar to other RT-PCR positive patients Why Read on: Our new HRCT classification when combined with RT-PCR can improve diagnostic accuracy while promptly improving triaging in COVID-19 patients.


  • Open Access

    Multidisciplinary management of hepatocellular carcinoma: a model for therapy

    by Gary S Cohen, Martin Black

    A multidisciplinary model is a useful approach in the management of hepatocellular carcinoma (HCC) to coordinate, individualize, and optimize care. The HCC Multidisciplinary Team (MDT) at Temple University Hospital was established in 2008 and comprises hepatologists, interventional radiologists, transplant surgeons, oncologists, residents, midlevel providers, and support staff. Patients may be enrolled by referral from (1) oncologists at Temple, (2) the hepatitis screening clinic recently established at Temple and staffed by hepatology residents, or (3) community practices. MDT conferences are held weekly, during which cases are discussed (based on medical history, interpretation of images, and laboratory analyses) and treatment plans are formulated. The Temple treatment algorithm follows current standards of care, guided by tumor volume and morphology, but the novel multidisciplinary interaction challenges members to tailor therapy to achieve the best possible outcomes. Patients with a solitary lesion ≤2 cm may receive no treatment until eligible for transplantation or locoregional therapy or resection, with imaging every 3 to 6 months to monitor tumor progression. In patients with tumors > 2 cm and ≤5 cm, microwave ablation therapy is used if lesions are discrete and accessible. Conventional transarterial chemoembolization (TACE) or drug-eluting bead TACE (DEB-TACE) or yttrium-90 microspheres are utilized in multifocal disease. Patients with lesions > 5 cm are candidates for TACE for downstaging the tumor. Sorafenib is typically reserved for unresectable lesions between 2 cm and 5 cm. Frequently, we administer sorafenib continuously and in combination with DEB-TACE. In our experience, sorafenib does not produce effects on the tumor vasculature or blood flow that would impair the efficacy of DEB-TACE. The literature documents improved outcomes in HCC and other cancers associated with the introduction of multidisciplinary care. The role and organization of the MDT is influenced by team culture, expertise, and process, as well as institutional and larger environmental contexts.